November 4, 2009 - Preclinical Studies Published in Science Translational Medicine Demonstrate that Therapeutic Administration of hSAP Inhibits Fibrosis
October 29, 2009 - European Commission Grants Promedior’s PRM-151 Orphan Drug Designation for the Prevention of Scarring Post Glaucoma Filtration Surgery
July 23, 2009 - Promedior Initiates Phase 1 Clinical Trial of PRM-151, a Novel Compound for the Treatment of Fibrotic Diseases and Tissue Remodeling
January 22, 2009 - Promedior’s Fibrosis Program Featured at Keystone Symposia Conference
January 5, 2009 - Promedior Announces Appointment of Dominick Colangelo as Chief Executive Officer
February 4, 2008 - Promedior Adds to Management Team and Announces Extension of Series A Financing
February 2, 2007 - Promedior Adds to Management Team
September 5, 2006 - Medior Announces Completion of Series A Financing Round and Appointment of CEO and Chairman

